Concizumab prophylaxis in people with hemophilia A or B without inhibitors: patient-reported outcome results from the phase 3 explorer8 study
PRO data from the phase 3 explorer8 study provided additional support for concizumab prophylaxis compared with no prophylaxis as a treatment option for patients with HA/HB.
Authors
- Guy A. Young (ORCID: https://orcid.org/0000-0001-6013-1254)
- Gary Benson (ORCID: https://orcid.org/0000-0002-4269-8713)
- Hermann Eichler (ORCID: https://orcid.org/0000-0002-1372-0619)
- Sylvia von Mackensen (ORCID: https://orcid.org/0000-0002-5926-0478)
- Laura Villarreal‐Martínez (ORCID: https://orcid.org/0000-0003-0313-7312)
- Amy Findley (ORCID: https://orcid.org/0000-0001-9887-6956)
- Pantep Angchaisuksiri (ORCID: https://orcid.org/0000-0001-5607-3485)
- Tadashi Matsushita (ORCID: https://orcid.org/0000-0002-3646-3125)
- Jameela Sathar (ORCID: https://orcid.org/0000-0003-1943-0863)
- Shashikant Apte (ORCID: https://orcid.org/0000-0002-5760-9680)
- Camila Martins Mazini Tavares
- Morten Puggaard Ravn
Institutions
- Universität Hamburg (DE)
- Hospital Kuala Lumpur (MY)
- Nagoya University Hospital (JP)
- University Medical Center Hamburg-Eppendorf (DE)
- KPJ Ampang Puteri Specialist Hospital (MY)
- Sahyadri Hospital (IN)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1016/j.rpth.2025.102705
- Citations
- 1
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Novo Nordisk